EBITDA for Insulet (PODD)
According to Insulet's latest reported financial statements, the company's current EBITDA (TTM) is $486.60M USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
PODD
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$486.60M
YoY change
+38.5%
5Y CAGR
+39.7%
Peak year (2025)
$586.90M
Cumulative EBITDA
$1.39B
EBITDA history chart for Insulet (PODD) from 2002 to 2025
EBITDA history table for Insulet (PODD) from 2002 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $586.90M | +38.5% | ||
| 2024 | $423.70M | +30.9% | ||
| 2023 | $323.60M | +196.9% | ||
| 2022 | $109.00M | -21.9% | ||
| 2021 | $139.60M | +26.6% | ||
| 2020 | $110.30M | +48.7% | ||
| 2019 | $74.20M | +57.5% | ||
| 2018 | $47.10M | +635.9% | ||
| 2017 | $6.40M | +356.2% | ||
| 2016 | $1.40M | -104.3% | ||
| 2015 | -$32.84M | +55.8% | ||
| 2014 | -$21.08M | +30.3% | ||
| 2013 | -$16.18M | -34.8% | ||
| 2012 | -$24.83M | -26.6% | ||
| 2011 | -$33.83M | +1.3% | ||
| 2010 | -$33.39M | -38.1% | ||
| 2009 | -$53.90M | -27.9% | ||
| 2008 | -$74.80M | +52.9% | ||
| 2007 | -$48.92M | +52.9% | ||
| 2006 | -$32.01M | +57.9% | ||
| 2005 | -$20.27M | +50.2% | ||
| 2004 | -$13.50M | +12.3% | ||
| 2003 | -$12.01M | -5.2% | ||
| 2002 | -$12.67M | — |
EBITDA values are taken from Insulet's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
In 2025, Insulet (PODD) EBITDA totalled $586.90M – surged 38.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Insulet EBITDA compounded at +39.7% per year, sustaining 3 straight years of year-over-year growth.
The dataset's maximum EBITDA sits at $586.90M (2025); the minimum reading of -$74.80M dates to 2008.
Among 8 Healthcare peers, Insulet (PODD) ranks 9th; the peer median for EBITDA is $25.50B.
Insulet EBITDA by Year
Insulet EBITDA 2025: $586.90M
Insulet EBITDA in 2025 was $586.90M, surged 38.5% from 2024. This figure represents the highest annual value in the available history.
Insulet EBITDA 2024: $423.70M
Insulet EBITDA in 2024 was $423.70M, surged 30.9% from 2023.
Insulet EBITDA 2023: $323.60M
Insulet EBITDA in 2023 was $323.60M, surged 196.9% from 2022.
Insulet EBITDA 2022: $109.00M
Insulet EBITDA in 2022 was $109.00M, declined 21.9% below 2021.
Insulet EBITDA 2021: $139.60M
Insulet EBITDA in 2021 was $139.60M.
See more financial history for Insulet (PODD).
Sector peers — EBITDA
Companies in the same sector as Insulet, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Merck & Co. (MRK) | $29.32B | Healthcare |
| Eli Lilly (LLY) | $27.94B | Healthcare |
| UnitedHealth Group (UNH) | $23.06B | Healthcare |
| AstraZeneca (AZN) | $19.83B | Healthcare |
| AbbVie (ABBV) | $17.63B | Healthcare |
| Amgen (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is Insulet's EBITDA?
Latest reported EBITDA for Insulet (PODD) is $486.60M (period ending December 31, 2025).
How has Insulet EBITDA changed year-over-year?
Insulet (PODD) EBITDA changed +38.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Insulet EBITDA?
Insulet (PODD) EBITDA compound annual growth rate is +39.7% over the most recent 5 years available.
When did Insulet EBITDA hit its highest annual value?
Insulet EBITDA reached its highest annual value of $586.90M in 2025.
What was Insulet EBITDA in 2024?
Insulet (PODD) EBITDA in 2024 was $423.70M.
What was Insulet EBITDA in 2025?
Insulet (PODD) EBITDA in 2025 was $586.90M.
PODD Key Financials
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
PODD Overview
Company profile, financial tools, and key metrics
PODD Revenue Counter
Earns $85.88 every second. See per minute, hour, and day.
PODD Earnings Counter
Earns $7.84 per second net profit. See per minute, hour, and day.
PODD Economic Scale
Exceeds St. Lucia's GDP. Compare with world economies.
PODD What If Invested
What if you had invested $1,000? See historical returns from any date.
PODD How It Makes Money
Discover visual breakdown of $2.71B in revenue — where it comes from and where it goes.
PODD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PODD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PODD Daily Price Character
Explosive · 51.5% historical win rate (green days). Streaks & record days.
PODD Buybacks
0.30% TTM buyback yield. Shareholder yield & SBC comparison.